CPT1A and chronic kidney disease: Resveratrol and its derivative, BEC2, have been experimentally confirmed as directly activating Cpt1A, thus accelerating long-chain fatty acid β-oxidation, but this class of drugs has not yet been used in animal CKD models [158,159].